Skip to main content
Premium Trial:

Request an Annual Quote

Paul Heaney, Samuel Kaplan, Joseph Nevins, James Schoeneck, Doug Boyd, John Harris, Douglas Morton

Premium

Paul Heaney, a former executive vice president at Sequenom, has been appointed to the scientific advisory board at CalbaTech.

Heaney was most recently executive vice president of research and technology at Sequenom, where his team developed the MassArray SNP-genotyping platform. He also worked as head of bioelectronics at Sarnoff, which led to the successful spin-out of Orchid Biosciences. Prior to that, he held positions at Amersham International, Kodak Clinical Diagnostics (now Ortho-Clinical Diagnostics), and Genometrix.


Samuel Kaplan, chairman of the department of microbiology at the University of Texas Houston Medical School, has been appointed to the scientific advisory board of CytoGenix.

Kaplan is an expert on the bacterium Rhodobacter sphaeroides, and is a collaborator in the R. sphaeroides genome project funded by the US Department of Energy. Kaplan has been at his current post since 1989. Before that, he was at the University of Illinois, Urbana from 1967 to 1989.

CytoGenix, of Houston, develops biopharmaceutical compounds using its gene-regulation technology.


Joseph Nevins has been appointed director of the Center for Genome Technology at Duke University.

Nevins, a professor of genetics at Duke and a Howard Hughes Medical Institute investigator, researches genes that control cell growth and the disruptions in genes that lead to development of cancerous tumors. In this new role, Nevins will be responsible for incorporating genome technologies in different research activities both at Duke Medical Center and on the main campus. He will step down as chair of the Duke department of genetics, a position he has held since the department was founded in 1991. He joined Duke in 1987.

The university is currently forming a search committee for the position of chair of the department of genetics, according to the statement released by the CGT.


James Schoeneck has been appointed CEO of ActivX Biosciences.

Schoeneck comes to ActivX from Prometheus Laboratories, where he was president and CEO. Prior to that, he was vice president of marketing and commercial development, and vice president and general manager of the immunology business unit at Centocor, a division of Johnson & Johnson.


Nanostream has hired Doug Boyd and John Harris as regional sales managers covering the eastern United States.

Boyd comes to Nanostream from biotechnology company Gyros. Before that, he worked for biotech-tool reseller Quantum Analytics. Harris, meantime, comes to Nanostream from Gilson, a manufacturer of laboratory robotics. Before that he worked for chemical synthesis equipment manufacturer Personal Chemistry, which Pyrosequencing acquired in September.


TissueInformatics has appointed former Pfizer vice president Douglas Morton to its board of directors.

Morton retired from Pfizer, where he was VP of worldwide discovery/strategic alliances. He is currently CEO of the Southwest Michigan Innovation Center. He is a graduate of Kenyon College, in Ohio, and received a PhD in chemistry from Columbia University, TissueInformatics said.

 

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.